1. Introduction {#s0005}
===============

Non-small cell lung cancer (NSCLC) accounts for nearly 70% of lung malignancy, which is the leading cause of cancer-related death worldwide and in China as well ([@b0010], [@b0095]). The silver lining is that precision medicine advances quite well in NSCLC ([@b0065]), with many targeted therapies currently available for NSCLC harboring specific mutations and rearrangements of oncogenes including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), RET and ROS proto-oncogene 1 (ROS1) ([@b0005]). For those without targetable mutations, platinum-based chemotherapy is the standard first-line treatment for NSCLC ([@b0080]). However, second-line and further treatments are usually needed for NSCLC due to frequent tumor resistance or recurrence ([@b0115]). Thus, other strategies such as antiangiogenesis that can be jointly or solely used for better disease control are needed ([@b0110]).

Given that most solid tumors are highly dependent on angiogenesis for nutrients and oxygen supply to support their growth, antiangiogenic therapy has been proven valuable in various scenarios ([@b0105]). Several strategies aiming to cut off the blood supply of NSCLC have been designed and antitumoral activity has been observed in some NSCLC patients; however, the efficacy were controversial and could be dependent on the antiangiogenic agents. For example, sorafenib is believed to be valuable in a subset of NSCLC patients ([@b0130]), while sunitinib failed to improve overall survival (OS) when combined with erlotinib in a phase III trial ([@b0090]). With more and more clinical trials of antiangiogenic agents being conducted, the benefits of a range of antiangiogenic agents have been clinically proved in NSCLC ([@b0035]). For instance, bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, showed OS benefit in patients with NSCLC when combined with carboplatin/paclitaxel (ECOG 4599 trial) or cisplatin/gemcitabine (AVAil trial) ([@b0075], [@b0085]). Ramucirumab, an anti-VEGF receptor (VEGFR)-2 antibody, showed better prognosis in patients with advanced NSCLC when combined with docetaxel (REVEL trial) ([@b0025]). Similarly, nintedanib, an oral triple angiokinase inhibitor, was also reported to significantly improve both progression-free survival (PFS) and OS in NSCLC patients (LUME-Lung 1 trial) ([@b0070]).

Apatinib is a novel oral VEGFR-2 tyrosine kinase inhibitor (TKI) and has been shown to improve prognosis in gastric cancer ([@b0040], [@b0045], 2016). Beside its antiangiogenic effect, it is reported that apatinib can enhance chemosensitization by reversing multidrug resistance ([@b0050]). Presently, many clinical trials are conducted to evaluate the antitumoral effects of apatinib ([@b0125]). Limited evidence also showed that apatinib provided some clinical benefits for patients with NSCLC ([@b0015], [@b0020], [@b0100]). Unfortunately, only 48 cases in total have been formally reported ([@b0015], [@b0020], [@b0060], [@b0100]). Therefore, the efficacy and toxicity of apatinib in NSCLC are far from understood and need further evaluation. Here, we reported the clinical use of apatinib in three cases of heavily treated NSCLC in our institute. Moreover, we reviewed currently available studies and registered clinical trials regarding the use of apatinib in NSCLC.

2. Case report {#s0010}
==============

2.1. Patient 1 {#s0015}
--------------

A 61-year-old male was admitted to our hospital because of chest tightness, cough, and right chest pain for four months. Computed tomography (CT) scan showed a lesion in his right lower lung. Proton emission tomography (PET)-CT confirmed the lesion with abnormally enhanced signal, and additionally revealed metastases in the hilar lymph nodes and possible metastasis in the 4th lumbar vertebral arch. Percutaneous pulmonary biopsy indicated pulmonary adenocarcinoma. The patient received pemetrexed/cisplatin doublet chemotherapy as first-line treatment and had a partial response (PR). Gefitinib was used at the 8th month of initial treatment since an EGFR mutation (L858R) was reported in the tumor tissue ([Table 1](#t0005){ref-type="table"}). The mass was found enlarged by CT scan 22 months later. After another seven months of pemetrexed/cisplatin treatment and a single dose of intrathoracic chemotherapy of cisplatin, the therapeutic evaluation was progression disease (PD). Docetaxel and pemetrexed were then sequentially administered until one year later we found more metastases in his left lung. The patient then tried AZD9291 for 4 months, erlotinib for 1 month, and AZD3759 for 4 months. Finally, apatinib (500 mg/day) was prescribed because of PD was considered following the treatment of up-mentioned drugs. The primary tumor and metastases in the left lung were significantly shrunk after a 3-week treatment of apatinib ([Fig. 1](#f0005){ref-type="fig"}A--C). Unfortunately, CT scan showed a response of PD merely another three weeks later. The patient died a few days later due to respiratory and circulatory failure. During the use of apatinib, the patients suffered from hand-foot syndrome (grade 3), mild diarrhea (grade 1), and controllable hypertension (grade 1) ([Table 2](#t0010){ref-type="table"}).Fig. 1Patient 1: Computed tomography showed the primary tumor in the right lung and metastases in the left lung (A) before apatinib treatment, (B) three weeks after apatinib treatment, and (C) six weeks after apatinib treatment. Arrows indicate tumoral cavitation.Table 1Clinical characteristics of the patients reported.Patient 1Patient 2Patient 3Age, year615973GenderMaleFemaleMalePathologyAdenocarcinomaAdenocarcinomaSquamous carcinoma  *Smoking*StageIV (T4N0M1)IV (T4N0M1)IV (T3N0M1)MutationEGFR L858RNoneEGFR L858R  *Therapy (response)* First linePemetrexed/cisplatin (PR)Docetaxel/cisplatin (SD)Gemcitabine/cisplatin (PR) Second lineGefitinib (SD)Pemetrexed/cisplatin (PD)Icotinib (PD) Third lineGefitinib Forth linePemetrexed/carboplatin (SD)[^1]Table 2Therapeutic results of apatinib in the patients.Patient 1Patient 2Patient 3EGFR-TKI co-therapyAZD3759GefitinibAZD9291Duration of apatinib treatment, days424622Withdrawal reasonPDPDHemoptysisPFS, months1.41.5--  *Adverse events* HypertensionGrade 1Grade 3-- Hand-foot syndromeGrade 3---- Hemorrhage----Grade 5 DiarrheaGrade 1---- Cardiac toxicity------ Bone marrow suppression------[^2]

2.2. Patient 2 {#s0020}
--------------

A 59-year-old female found an elevated level of carcinoembronic antigen during her regular physical examination. PET-CT showed a mass in the left lower lung and multiple metastases in both lungs. Lymphadenectasis of hilus and mediastinum was also suggested by imaging. Percutaneous biopsy indicated pulmonary adenocarcinoma, and no gene mutation was detected. The patient was firstly treated by docetaxel/cisplatin doublet chemotherapy for six months and had a response of stable disease (SD). The patient then tried pemetrexed monotherapy for four months and tried combination of pemetrexed and cisplatin for another five months. The therapeutic evaluation was PR. Gefitinib was then prescribed and a PFS of 15 months was achieved. The patient then underwent pemetrexed/cisplatin doublet chemotherapy again for three months and the response was still SD. After that, the patient received apatinib (500 mg/day) for three weeks, and CT scan suggested reduced volume of primary and metastatic lesions ([Fig. 2](#f0010){ref-type="fig"}A--C). However, new metastases were identified in the lungs 25 days later, and apatinib was ceased, with a monotherapy of gefitinib. The patient had significantly increased blood pressure that was up to 175/110 mmHg during apatinib treatment.Fig. 2Patient 2: Computed tomography showed primary tumor the right lung and metastases in the left lung (A) before apatinib treatment, (B) three weeks after apatinib treatment, and (C) 46 days after apatinib treatment. Arrows indicate tumoral cavitation.

2.3. Patient 3 {#s0025}
--------------

A 73-year-old male was admitted due to cough and pulmonary tightness. Chest CT scan presented with consolidation and bronchial obstruction of left upper lobe, and left pleural effusion was observed. Electronic bronchoscopy showed a neoplastic lesion in the left upper lobe, and squamous carcinoma was confirmed by pathology. An EGFR (L858R) mutation was reported ([Table 1](#t0005){ref-type="table"}). Doublet chemotherapy of gemcitabine/carboplatin was prescribed for two months and then icotinib was used as second-line therapy for another month. Apatinib (500 mg/day) combined with AZD9291 was administered as the third-line therapy. The patient was treated with apatinib for a total of three weeks and his clinical symptoms were relieved and partial re-expansion of the left lung was noticed ([Fig. 3](#f0015){ref-type="fig"}A and B). Unfortunately, the patient died of massive hemoptysis suddenly one week later.Fig. 3Patient 3: Computed tomography showed primary tumor the right lung (A) before and (B) two weeks after apatinib treatment.

3. Discussion {#s0030}
=============

According to the previous reports, the median PFS in NSCLC patients with apatinib treatment was around five months ([Table 3](#t0015){ref-type="table"}) ([@b0020], [@b0060], [@b0100], [@b0135]), which was longer than that in patients with gastric cancer ([@b0040], [@b0045], 2016). The disease control rate was approximately 60--85% ([@b0100], [@b0120], [@b0135]), and the OS was 4--6 months for NSCLC patients ([Table 3](#t0015){ref-type="table"}) ([@b0100], [@b0120]). However, since apatinib was mostly used in NSCLC as a third- or forth-line therapy, PFS rather than OS may be a more suitable indicator to reflect the efficacy of apatinib. Although our cases responded to apatinib rapidly, their PFS was short ([Table 2](#t0010){ref-type="table"}). For the first case, the bad pulmonary function at the beginning of apatinib treatment might limit the efficacy of apatinib. The second case had been heavily treated before apatinib was prescribed, and the tumor might have already become extremely malignant because of the selection by different drugs. The third patient died unexpectedly and we could not evaluate the actual efficacy of apatinib. Although only a few publications regarding apatinib for lung cancer are available now, dozens of clinical trials are ongoing or in preparation ([Table 4](#t0020){ref-type="table"}). We can expect more evidence in near future.Table 3Clinical data of previously reported study.[@b0020][@b0015][@b0060][@b0100][@b0120][\*](#tblfn1){ref-type="table-fn"}[@b0130], [@b0135][\#](#tblfn2){ref-type="table-fn"}InstituteThe First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, ChinaChina-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, ChinaZhejiang Cancer Hospital, Hangzhou, ChinaSi Chuan Cancer Hospital, Chengdu, ChinaTwenty centers in ChinaPathologyNSCLC, EGFR(--), ALK(--)Poor differentiated adenocarcinoma, squamous carcinomaNSCLCNSCLCMetastatic NSCLC, EGFR(--)Non-squamous NSCLCNo. of patients321422090Line of treatmentPost third lineSecond and forth lineThird linePost second linePost third linePost third lineDosage, mg/day500850250 or 500500500750ORR100%50%100%9.5%30%20%DCR100%100%100%61.9%85%68.9%PR3/31/21/14/42NRNRSD0/31/20/122/42NR51/90PFS, months2.8--6.04.6, 6.05.14.2NR4.7OS, monthsNRNRNR6.04NRAdverse events (Grade 3/4)2/3NR1/121/42Hypertension (5%), HFS (5%), hemoptysis (5%)NR[^3][^4][^5]Table 4Clinical trials for the use of apatinib in lung cancer.Registration No.DiseaseTreatmentSample sizePrimary outcomeStatusInstituteStudy typeChiCTR-OPC-17011039[\*](#tblfn3){ref-type="table-fn"}NSCLC, stage IIIB/IV, IIIA (not suitable for surgery)Apatinib + RFA30PFSRecruitingSir Run Run Shaw Hospital, Hangzhou, ChinaObservationalChiCTR-OPC-17011020[\*](#tblfn3){ref-type="table-fn"}Advanced refractory NSCLC, VEGFR-2 positiveApatinib30DCR, ORR, MSTRecruiting101th Hospital of PLA, Wuxi, ChinaObservationalChiCTR-OIC-1701101[\*](#tblfn3){ref-type="table-fn"}Recurrent and metastatic small cell lung cancerApatinib + etoposide60PFSPendingThe Affiliated Tumor Hospital Of General Hospital Of Ningxia Medical University, Yinchuan, ChinaObservational, Phase IIChiCTR-IPR-17010776[\*](#tblfn3){ref-type="table-fn"}Advanced non-squamous NSCLC harboring EGFR mutations, stage IIIB/IVGefitinib + apatinib30PFSPendingThe First Affiliated Hospital of the Third Military Medical University, Chongqing, ChinaFirst-line RCTChiCTR-IPR-17010361[\*](#tblfn3){ref-type="table-fn"}Small cell lung cancer, stage IVEP regimen + apatinib60PFSPendingThe North Hospital of the Affiliated Hospital of Qingdao University, Qingdao, ChinaFirst-line RCTChiCTR-OPC-16009894[\*](#tblfn3){ref-type="table-fn"}Non-squamous NSCLC without EGFR mutation, stage IIIB/IVApatinib + cisplatin/docetaxel40PFSRecruitingThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, ChinaObservationalChiCTR-OPC-16009048[\*](#tblfn3){ref-type="table-fn"}Advanced squamous cell lung cancerApatinib + S-130PFSRecruitingAnhui Chest Hospital, Hefei, ChinaSecond-line ObservationalChiCTR-OPN-16008694[\*](#tblfn3){ref-type="table-fn"}\
NCT02852798[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC with wild-type EGFR, stage III/IVApatinib + docetaxel60PFSPendingDongguan People's Hospital, Dongguan, ChinaSecond-line ObservationalChiCTR-OOC-16008238[\*](#tblfn3){ref-type="table-fn"}Advanced non-squamous NSCLCApatinib + Xiaoyan Tang30PFS, adverse effectRecruitingThe First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaObservationalChiCTR-OPN-15007443[\*](#tblfn3){ref-type="table-fn"}Advanced squamous cell lung cancerApatinib + docetaxel60PFSRecruitingThe Second People's Hospital of Lianyungang, Lianyungang, ChinaObservationalNCT02515435[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLCApatinib40ORRRecruitingShanghai Pulmonary Hospital, Tongji University, Shanghai, ChinaPhase II, post third lineNCT02540824[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC with positive RET fusionApatinib40ORRRecruitingShanghai Pulmonary Hospital, Tongji University, Shanghai, ChinaPhase II, post first lineNCT02493582[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC with wild-type EGFR, stage IIIB/IVApatinib + CIK400OSOngoingThe First People's Hospital of Changzhou, Changzhou, ChinaPhase II, third line, RCTNCT03129256[\#](#tblfn4){ref-type="table-fn"}NSCLCApatinib + S-152PFSRecruitingChangzhou Cancer Hospital of Soochow University, Soochow, ChinaPhase II, post first lineNCT02974933[\#](#tblfn4){ref-type="table-fn"}Advance non-squamous NSCLC, stage IIIB/IVApatinib + pemetrexed48PFSRecruitingHubei Cancer Hospital, Wuhan, ChinaPhase IINCT02875457[\#](#tblfn4){ref-type="table-fn"}Small cell lung cancer, extensive stageApatinib + etoposideand cisplatin100PFSRecruitingDaping Hospital, The Third Military Medical University, Chongqing, ChinaPhase IIINCT02733107[\#](#tblfn4){ref-type="table-fn"}Advanced NSCLC with wild-type EGFRApatinib + etoposide25PFSRecruitingDaping Hospital, The Third Military Medical University, Chongqing, ChinaPhase II, post first lineNCT03083041[\#](#tblfn4){ref-type="table-fn"}Advanced NSCLCApatinib + SHR-1210118Adverse events, ORRRecruitingShanghai Pulmonary Hospital, Tongji University, Shanghai, ChinaPhase II, post first/s lineNCT03050411[\#](#tblfn4){ref-type="table-fn"}Advanced EGFR-TKI resistant NSCLCApatinib + EGFR-TKIs30Optimal dosage, PFSRecruitingPeking University Third Hospital, Beijing, ChinaPhase INCT02332512[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC harboring wild-type EGFRApatinib417OSRecruitingSun Yet-sen University, Guangzhou, China; Shanghai Pulmonary Hospital, Shanghai, ChinaPhase III, RCT, post second lineNCT01270386[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLCApatinib136PFSCompletedSun Yat-sen University, Guangzhou, ChinaPhase II, RCT, post second lineNCT02945852[\#](#tblfn4){ref-type="table-fn"}Refractory small cell lung cancerApatinib30PFSRecruitingZhejiang Cancer Hospital, Hangzhou, ChinaPhase II, post second lineNCT02691871[\#](#tblfn4){ref-type="table-fn"}Advanced lung cancer harboring wild-type EGFR, stage IVApatinib + docetaxel20MTD, DLTPendingCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, ChinaPhase I, second lineNCT02780778[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC harboring wild-type EGFRApatinib + docetaxel20PFSRecruitingTianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaPhase II/III, second lineNCT02980809[\#](#tblfn4){ref-type="table-fn"}Small cell lung cancer, limited or extensive stageApatinib + topotecan *vs.* topotecan60PFSPendingFirst Hospitals affiliated to the China PLA General Hospital, Beijing, ChinaPhase II, second lineNCT03127319[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC harboring wild-type EGFR with bone metastasesApatinib + docetaxel/zoledronic40PFSPendingAffiliated Hospital of Hebei University, Baoding, ChinaPhase II, post first lineNCT02995187[\#](#tblfn4){ref-type="table-fn"}Small cell lung cancerApatinib25PFSPendingChinese Academy of Medical Sciences, Beijing, ChinaPhase II, post second lineNCT02704767[\#](#tblfn4){ref-type="table-fn"}Lung cancer with mutant EGFRApatinib + erlotinib *vs.* erlotinib60PFSPendingThe First Affiliated Hospital of Kunming Medical College, Kunming, ChinaPhase IINCT03100955[\#](#tblfn4){ref-type="table-fn"}Small cell lung cancer, extensive stageApatinib + cisplatin/etoposide120PFSRecruitingAffiliated Hospital of Qingdao University, Qingdao, ChinaPhase III, RCTNCT03129698[\#](#tblfn4){ref-type="table-fn"}Small cell lung cancer, extensive stageApatinib52PFSRecruitingPeking Union Medical College, Beijing, ChinaPhase IINCT02824458[\#](#tblfn4){ref-type="table-fn"}Advanced non-squamous NSCLC harboring EGFR mutations, stage IIIB/IVApatinib + gefitinib *vs.* Gefitinib246DLT, MTD, PFSRecruitingSun Yat-sen University, Guangzhou, ChinaPhase III, RCT[^6][^7][^8][^9]

The well-known adverse events of apatinib are hand-foot syndrome, proteinuria, and hypertension, because of the antiangiogenetic effects of apatinib in other organs ([@b0040], [@b0045], 2016). At a dose of 500 mg/day, the adverse events of apatinib are acceptable, with a grade-3 toxicity rate of 50% and no grade 4 toxicity ([@b0100]). No grade 4 adverse events were found in our patients, but unfortunately, the third case died of sudden hemoptysis (grade 5). Although we have no definite conclusion regarding the causality between hemoptysis and apatinib treatment, a potentially increased risk of squamous cell lung cancer should be pay more attention to when apatinib is considered to be used in NSCLC patients.

With more data acquired from gastric cancer, the dose of apatinib was recommended as 850 mg/day by a phase II trial ([@b0040]). At this dosage, the incidences of severe adverse events were similar between apatinib- and placebo-treated groups, except for a slightly increased incidence of hypertension (around 10%). However, in previous reports of apatinib for NSCLC, a dose of 500 mg/day was more commonly adopted ([Table 3](#t0015){ref-type="table"}) ([@b0020], [@b0100]). A patient received 250 mg/day of apatinib could still have a PR as shown in a case report ([@b0060]). In addition, the case showed a dynamic change of tumor volume according to the use and dose adjustment of apatinib, suggesting that the efficacy of apatinib was dose-dependent. Thus, for NSCLC patients with normal weights, the dose of apatinib is recommended to be initiated at 500 mg/per and can be further adjusted in case of severe adverse events.

Since EGFR-TKI is frequently used in NSCLC, the combination of apatinib and EGFR-TKI is common. Actually, EGFR-TKI was continuously used when our patients were prescribed with apatinib ([Table 2](#t0010){ref-type="table"}). In Song's cohort, the two patients with apatinib and EGFR-TKI co-therapy gained a much longer PFS (11.0 and 9.0 months, respectively) than the median PFS of their whole cohort (4.2 months) ([@b0100]). In another case report, apatinib was believed to overcome EGFR-TKI resistance of NSCLC and obtained another 5.1-month PFS for the patient ([@b0060]). These findings shed a light on the combination therapy of EGFR-TKI and apatinib in NSCLC.

Tumoral cavitation in CT scan is frequently observed during apatinib treatment. Two out of three patients in our case series displayed cavitation formation. This phenomenon was also observed in previous studies, in which some but not all patients displayed tumoral cavication after apatinib treatment ([@b0015], [@b0020], [@b0135]). Similarly, tumoral cavication was reported in patients receiving bevacizumab treatment. In patients with NSCLC, 19% cases were reported to develop cavitation during bevacizumab treatment ([@b0055]). However, no difference in terms of PFS or OS was found between patients with or without tumoral cavitation. Cavication reduces tumor volume, thus can be a sign of tumor response to the treatment. However, whether tumoral cavication correlates with patients' prognosis needs further investigation. Tumoral cavitation is probably due to necrosis of tumor cells in tumor core where blood supply is extensively affected during antiangiogenic therapy.

Since a high rate of hemoptysis was associated with squamous NSCLC in patients treated with bevacizumab in a phase II trial ([@b0030]), squamous NSCLC is usually a contraindication for bevacizumab. One of our patients with squamous NSCLC died of hemoptysis during apatinib treatment. However, in Song's cohort, nearly 30% of the included patients had squamous NSCLC and no hemoptysis was reported after apatinib treatment ([@b0100]). Therefore, the risk of hemoptysis in squamous NSCLC patients is inconclusive and current limited data suggest that squamous NSCLC may be not a contraindication of apatinib. Currently, at least two ongoing clinical trials of apatinib include patients with squamous NSCLC, and will provide more evidence to answer this question ([Table 4](#t0020){ref-type="table"}).

4. Conclusion {#s0035}
=============

With the report of three cases and literature review, we conclude that apatinib can be used in heavily treated NSCLC patients. Apatinib can induce some responses in NSCLC patients with tolerable toxicity. However, more evidence is urgently needed.

Conflict of interests {#s0040}
=====================

None.

This study is financially supported by the General Medical Association of Anhui Province (No. 2016QK069).

Peer review under responsibility of King Saud University.

[^1]: *Abbreviations:* EGFR, epidermal growth factor receptor; PD, progression disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

[^2]: *Abbreviations:* PD, progression disease; PFS, progression-free survival; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.

[^3]: *Abbreviations:* ALK, anaplastic lymphoma kinase; DCR, disease control rate; EGFR, epidermal growth factor receptor; HFS, hand-foot syndrome; NR, not reported; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease.

[^4]: Presented at ESMO Asia 2016 Congress, only abstract available.

[^5]: Presented at 2012 ASCO Annual Meeting, only abstract available.

[^6]: *Abbreviations:* CIK, cytokine-induced killer cell; DCR, disease control rate; DLT, dose limited toxicity; EGFR, epidermal growth factor receptor; MST, median survival time; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PLA, People's liberty army; RCT, randomized controlled trial; RFA: radiofrequency ablation; TKI, tyrosine kinase inhibitor.

[^7]: Note: EP regimen: EP, 80 mg/m^2^, D1; cisplatin, etoposide 100 mg/m^2^, D1-3.

[^8]: Registered at Chinese Clinical Trial Registry.

[^9]: Registered at [ClinicalTrial.gov](http://ClinicalTrial.gov){#ir005}.
